0001757898-20-000008.txt : 20200513 0001757898-20-000008.hdr.sgml : 20200513 20200513164728 ACCESSION NUMBER: 0001757898-20-000008 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200513 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200513 DATE AS OF CHANGE: 20200513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STERIS plc CENTRAL INDEX KEY: 0001757898 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38848 FILM NUMBER: 20873775 BUSINESS ADDRESS: STREET 1: 70 SIR JOHN ROGERSON'S QUAY CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 35312322000 MAIL ADDRESS: STREET 1: 70 SIR JOHN ROGERSON'S QUAY CITY: DUBLIN STATE: L2 ZIP: 2 FORMER COMPANY: FORMER CONFORMED NAME: STERIS Ltd DATE OF NAME CHANGE: 20181101 8-K 1 ste03312020form8-k.htm 8-K Document
false0001757898falseL2falsefalse 0001757898 2020-05-13 2020-05-13


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 13, 2020
STERIS plc
(Exact Name of Registrant as Specified in Charter)

Ireland
 
001-38848
 
98-1455064
(State or other jurisdiction of
incorporation or organization)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
 
 
 
 
70 Sir John Rogerson's Quay,
Dublin 2,
Ireland
D02 R296
(Address of principal executive offices)
Registrant’s telephone number, including area code: + 353 1 232 2000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
 
 
 
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Ordinary Shares
 
STE
 
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐





Item 2.02
Results of Operations and Financial Condition.

On May 13, 2020, STERIS plc (the “Company”) issued a press release announcing financial results for the three and twelve month periods ending March 31, 2020 and an interim dividend. A copy of this press release is attached hereto as Exhibit 99.1.
The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this Item 2.02 of this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits:
 
 
 
 
 
Exhibit
No.
  
Description
99.1
  
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
STERIS plc
 
 
 
 
By
 
/s/ J. Adam Zangerle
 
Name:
 
J. Adam Zangerle
 
Title:
 
Senior Vice President, General Counsel & Secretary
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dated: May 13, 2020



 EX-99.1 2 ste03312020ex991.htm EXHIBIT 99.1 Exhibit


 
 
 
 
Exhibit 99.1
                                                
STERIS Announces Financial Results for Fiscal 2020 Fourth Quarter and Full Year
•
Strong fourth quarter and full year revenue growth and profitability
•
Company not providing guidance for fiscal 2021 at this time due to COVID-19


DUBLIN, IRELAND - (May 13, 2020) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2020 fourth quarter ended March 31, 2020. Revenue as reported for the quarter increased 7% to $823.0 million compared with $768.2 million in the fourth quarter of fiscal 2019, with growth across all segments. Constant currency organic revenue (see Non-GAAP Financial Measures) growth was 8% for the fourth quarter of fiscal 2020.
      
“We are pleased to end fiscal 2020 with such strong performance,” said Walt Rosebrough, President and Chief Executive Officer of STERIS. “We experienced modest financial impact from a decline in procedure volumes late in the fourth quarter due to COVID-19. Because of the uncertainty of COVID-19, we are not providing guidance for fiscal 2021 at this time. We continue to leverage our capabilities to assist healthcare providers on the front lines of this pandemic.”

Fourth Quarter and Full Year Operating Results
As reported, net income for the fourth quarter was $123.3 million, or $1.44 per diluted share, compared with net income of $108.7 million, or $1.27 per diluted share in the fourth quarter of fiscal 2019. Adjusted net income (see Non-GAAP Financial Measures) for the fourth quarter of fiscal 2020 was $140.5 million, or $1.64 per diluted share, compared with adjusted net income for the previous year’s fourth quarter of $131.1 million or $1.53 per diluted share. As reported, full year net income was $407.6 million, or $4.76 per diluted share, compared with $304.1 million, or $3.56 per diluted share in fiscal 2019. Adjusted net income increased 16% to $482.6 million, or $5.64 per diluted share, compared with adjusted net income of $417.5 million, or $4.89 per diluted share in fiscal 2019.

Fourth Quarter Segment Results
Healthcare Products revenue as reported grew 3% in the quarter to $397.8 million compared with $386.6 million in the fourth quarter of fiscal 2019, driven by 10% growth in consumable revenue and 3% growth in service revenue partially offset by a 1% decline in capital equipment revenue. Constant currency organic revenue growth for Healthcare Products was 3% during the quarter. Healthcare Products operating income was $105.9 million compared with $106.7 million in last year’s fourth quarter, primarily due to an 11% increase in R&D spending.

Healthcare Specialty Services as reported revenue grew 10% in the quarter to $148.8 million compared with $135.5 million in the fourth quarter of fiscal 2019. Constant currency organic revenue growth was 11%. Healthcare Specialty Services operating income was $16.0 million compared with $19.8 million in last year’s fourth quarter, benefiting from the increase in revenue, which was more than offset by investments being made to add capacity in anticipation of continuing demand.

Note: Effective April 1, 2020, and consistent with the way management will operate and view the business, the current Healthcare Products and Healthcare Specialty Services segments will be combined and reported as one segment, simply called Healthcare. Going forward we will operate and report in three business segments: Healthcare, Life Sciences and Applied Sterilization Technologies. Corporate will continue to be presented separately and contain the costs that are associated with being a publicly traded company and certain other corporate costs. Please see the attached financial tables for a recast of fiscal 2020 quarterly results under the new segments.

Fiscal 2020 fourth quarter revenue for Applied Sterilization Technologies increased 14% as reported to $163.7 million compared with $143.1 million in the same period last year. Constant currency organic revenue increased 15%, primarily driven by increased volume from the segment’s core medical device Customers. Segment




operating income increased to $72.0 million in the fourth quarter of fiscal 2020 compared with operating income of $57.4 million in the same period last year, due primarily to revenue growth.

Life Sciences fourth quarter revenue as reported grew 9% to $112.7 million compared with $103.0 million in the fourth quarter of fiscal 2019, driven by 26% growth in consumable revenue and 5% growth in service revenue partially offset by a 9% decline in capital equipment revenue. Constant currency organic revenue grew 10% in the quarter. Operating income was $41.0 million compared with $35.9 million in the prior year’s fourth quarter, primarily driven by the increase in volume.

Cash Flow
Net cash provided by operations for fiscal 2020 was $590.6 million, compared with $539.5 million in fiscal 2019. Free cash flow (see Non-GAAP Financial Measures) for fiscal 2020 was $380.2 million compared with $355.4 million in the prior year. The increase in free cash flow is primarily due to the improvement in cash from operations.

Dividend Announcement
STERIS’s Board of Directors has approved a quarterly interim dividend of $0.37 per share. The dividend is payable June 26, 2020 to shareholders of record at the close of business on June 12, 2020.

Conference Call
As previously announced, STERIS management will host a conference call tomorrow, May 14, 2020 at 10:00 a.m. Eastern time. The conference call can be heard live over the Internet at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.

For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. Eastern Time on May 14, 2020, either over the Internet at www.steris-ir.com or via phone. To access the replay of the call, please use the access code 10142845 and dial 1-877-344-7529 in the United States or 1-412-317-0088 internationally.

About STERIS
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe. For more information, visit www.steris.com.

Investor Contact:
Julie Winter, Senior Director, Investor Relations and Corporate Communications
Julie_Winter@steris.com
+1 440 392 7245

Media Contact:
Stephen Norton, Senior Director, Corporate Communications
Stephen_Norton@steris.com
+1 440 392 7482

Non-GAAP Financial Measures
Adjusted net income, free cash flow and constant currency organic revenue are non-GAAP measures that may be used from time to time and should not be considered replacements for GAAP results.  Non-GAAP financial measures are presented in this release with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and




analyzing the underlying performance of our operations for the periods presented.  The Company believes that the presentation of these non-GAAP financial measures, when considered along with our GAAP financial measures, provides a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure.

Adjusted net income excludes the amortization of intangible assets acquired in business combinations, acquisition related transaction costs, integration costs related to acquisitions, redomiciliation and tax restructuring costs, COVID-19 incremental costs, and certain other unusual or non-recurring items. COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available. STERIS believes this measure is useful because it excludes items that may not be indicative of or are unrelated to our core operating results and provides a baseline for analyzing trends in our underlying businesses.

The Company defines free cash flow as cash flows from operating activities less purchases of property, plant, equipment and intangibles, plus proceeds from the sale of property, plant, equipment, and intangibles. STERIS believes that free cash flow is a useful measure of the Company’s ability to fund future principal debt repayments and growth outside of core operations, pay cash dividends, and repurchase ordinary shares.

To measure the percentage organic revenue growth, the Company removes the impact of significant acquisitions and divestitures that affect the comparability and trends in revenue. To measure the percentage constant currency organic revenue growth, the impact of changes in currency exchange rates and acquisitions and divestitures that affect the comparability and trends in revenue are removed. The impact of changes in currency exchange rates is calculated by translating current year results at prior year average currency exchange rates.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies’ non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales, gross profit, operating income, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

Forward-Looking Statements
This release and the referenced conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend”, and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in laws, government regulations, labeling or product approvals or the application or interpretation thereof. Other risk factors are described in STERIS’s other securities filings, including Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2019. Many of these important factors are outside of STERIS’s control. No assurances can be provided as to any result or the timing of any outcome regarding matters described in STERIS’s securities filings or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, cost reductions, business strategies, earnings or revenue




trends or future financial results. References to products are summaries only and should not be considered the specific terms of the product clearance or literature. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the impact of the COVID-19 pandemic on STERIS’s operations, performance, results, prospects, or value, (b) STERIS's ability to achieve the expected benefits regarding the accounting and tax treatments of the redomiciliation to Ireland (“Redomiciliation”), (c) operating costs, Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected following the Redomiciliation, (d) STERIS’s ability to meet expectations regarding the accounting and tax treatment of the Tax Cuts and Jobs Act (“TCJA”) or the possibility that anticipated benefits resulting from the TCJA will be less than estimated, (e) changes in tax laws or interpretations that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, (f) the potential for increased pressure on pricing or costs that leads to erosion of profit margins, (g) the possibility that market demand will not develop for new technologies, products or applications or services, or business initiatives will take longer, cost more or produce lower benefits than anticipated, (h) the possibility that application of or compliance with laws, court rulings, certifications, regulations, regulatory actions, including without limitation any of the same relating to FDA, EPA or other regulatory authorities, government investigations, the outcome of any pending or threatened FDA, EPA or other regulatory warning notices, actions, requests, inspections or submissions, or other requirements or standards may delay, limit or prevent new product or service introductions, affect the production, supply and/or marketing of existing products or services or otherwise affect STERIS’s performance, results, prospects or value, (i) the potential of international unrest, economic downturn or effects of currencies, tax assessments, tariffs and/or other trade barriers, adjustments or anticipated rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs, (j) the possibility of reduced demand, or reductions in the rate of growth in demand, for STERIS’s products and services, (k) the possibility of delays in receipt of orders, order cancellations, or delays in the manufacture or shipment of ordered products or in the provision of services, (l) the possibility that anticipated growth, cost savings, new product acceptance, performance or approvals, or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with STERIS’s businesses, industry or initiatives including, without limitation, those matters described in our Annual Report on Form 10-K for the year ended March 31, 2019, and other securities filings, may adversely impact STERIS’s performance, results, prospects or value, (m) the impact on STERIS and its operations, or tax liabilities, of Brexit or the exit of other member countries from the EU, and the Company’s ability to respond to such impacts, (n) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade or tax legislation, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto, (o) the possibility that anticipated financial results or benefits of recent acquisitions, or of STERIS’s restructuring efforts, or of recent divestitures, or of restructuring plans will not be realized or will be other than anticipated, and (p) the effects of contractions in credit availability, as well as the ability of STERIS’s Customers and suppliers to adequately access the credit markets when needed.






STERIS plc
 
 
 
 
 
 
 
 
Consolidated Condensed Statements of Operations
 
 
 
 
 
 
 
 
(In thousands, except per share data)
 
 
 
 
 
 
 
 
 
 
Three Months Ended March 31,

Twelve Months Ended March 31,
 
 
2020

2019

2020

2019
 
 
(Unaudited)
 
(Unaudited)
 
(Unaudited)
 
(Unaudited)
Revenues
 
$
822,991

 
$
768,213

 
$
3,030,895

 
$
2,782,170

Cost of revenues, net
 
459,122

 
432,872

 
1,708,502

 
1,597,022

Total cost of revenues - restructuring
 
(191
)
 
625

 
2,470

 
9,721

Total cost of revenues
 
458,931

 
433,497

 
1,710,972

 
1,606,743

Gross profit
 
364,060

 
334,716

 
1,319,923

 
1,175,427

Operating expenses:
 
 
 
 
 
 
 
 
Selling, general, and administrative
 
189,064

 
173,120

 
716,731

 
669,937

Research and development
 
17,225

 
15,878

 
65,546

 
63,038

Restructuring expenses
 
6

 
4,840

 
673

 
30,987

Total operating expenses
 
206,295

 
193,838

 
782,950

 
763,962

 
 
 
 
 
 
 
 
 
Income from operations
 
157,765

 
140,878

 
536,973

 
411,465

Non-operating expenses, net
 
9,753

 
7,478

 
38,292

 
41,995

Income tax expense
 
24,793

 
24,523

 
90,876

 
64,394

Net income
 
$
123,219

 
$
108,877

 
$
407,805

 
$
305,076

Less: Net (loss) income attributable to noncontrolling interests
 
(97
)
 
132

 
200

 
1,025

Net income attributable to shareholders
 
$
123,316

 
$
108,745

 
$
407,605

 
$
304,051

 
 
 
 
 
 
 
 
 
Earnings per ordinary share (EPS) data:
 
 
 
 
 
 
 
 
Basic
 
$
1.45

 
$
1.29

 
$
4.81

 
$
3.59

Diluted
 
$
1.44

 
$
1.27

 
$
4.76

 
$
3.56

 
 
 
 
 
 
 
 
 
Cash dividends declared per share ordinary outstanding
 
$
0.37

 
$
0.34

 
$
1.45

 
$
1.33

 
 
 
 
 
 
 
 
 
Weighted average number of shares outstanding used in EPS computation:
 
 
 
 
 
 
 
 
  Basic number of shares outstanding
 
84,891

 
84,546

 
84,778

 
84,577

  Diluted number of shares outstanding
 
85,676

 
85,447

 
85,641

 
85,468

STERIS plc
 
 
 
 
Consolidated Condensed Balance Sheets
 
 
 
 
(in thousands)
 
 
 
 
 
 
March 31,
 
March 31,
 
 
2020
 
2019
 
 
(Unaudited)
 
 
Assets
 
 
 
 
Current assets:
 
 
 
 
Cash and cash equivalents
 
$
319,581

 
$
220,633

Accounts receivable, net
 
586,481

 
564,830

Inventories, net
 
248,259

 
208,243

Prepaid expenses and other current assets
 
54,430

 
60,029

Total current assets
 
1,208,751

 
1,053,735

 
 
 
 
 
Property, plant, and equipment, net
 
1,111,855

 
1,031,582

Lease right-of-use assets, net
 
131,837

 
—

Goodwill
 
2,356,085

 
2,322,928

Intangibles, net
 
565,473

 
604,614

Other assets
 
51,581

 
60,212

Total assets
 
$
5,425,582

 
$
5,073,071

Liabilities and equity
 
 
 
 
Current liabilities:
 
 
 
 
Accounts payable
 
149,341

 
$
152,913

Other current liabilities
 
354,266

 
312,283

Total current liabilities
 
503,607

 
465,196

Long-term indebtedness
 
1,150,521

 
1,183,227

Other liabilities
 
364,730

 
238,850

Total equity
 
3,406,724

 
3,185,798

Total liabilities and equity
 
$
5,425,582

 
$
5,073,071





STERIS plc
 
 
 
 
Segment Data
 
 
 
 
 
 
 
 
 
Financial information for each of the segments is presented in the following table. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. Segment income is calculated as the segment’s gross profit less direct costs and indirect costs if the resources are dedicated to a single segment. Corporate costs include corporate and administrative functions, public company costs, legacy post-retirement benefits, and certain services and facilities related to distribution and research and development that are shared by multiple segments.

 
 
Three Months Ended March 31,
 
Twelve Months Ended March 31,
 
 
2020
 
2019
 
2020

2019
Revenues:
 
(Unaudited)
 
(Unaudited)
 
(Unaudited)
 
(Unaudited)
Healthcare Products
 
$
397,777

 
$
386,649

 
$
1,423,198

 
$
1,338,428

Healthcare Specialty Services
 
148,795

 
135,493

 
563,611

 
510,057

Life Sciences
 
112,731

 
102,987

 
416,939

 
378,558

Applied Sterilization Technologies
 
163,688

 
143,084

 
627,147

 
555,127

Total revenues
 
$
822,991

 
$
768,213

 
$
3,030,895

 
$
2,782,170

Operating income (loss):
 
 
 
 
 
 
 
 
Healthcare Products
 
$
105,909

 
$
106,673

 
$
356,419

 
$
323,684

Healthcare Specialty Services
 
15,950

 
19,800

 
64,217

 
64,222

Life Sciences
 
41,003

 
35,869

 
144,088

 
132,129

Applied Sterilization Technologies
 
72,028

 
57,411

 
270,917

 
221,828

Corporate
 
(55,402
)
 
(49,847
)
 
(207,015
)
 
(184,900
)
Total operating income before adjustments
 
$
179,488

 
$
169,906

 
$
628,626

 
$
556,963

Less: Adjustments
 
 
 
 
 
 
 
 
Amortization of acquired intangible assets
 
$
18,268

 
$
17,971

 
$
71,675

 
$
86,878

Acquisition and integration related charges
 
2,640

 
2,704

 
8,225

 
8,901

Redomiciliation and tax restructuring costs
 
425

 
3,150

 
3,699

 
8,783

(Gain) on fair value adjustment of acquisition related contingent consideration
 
—

 
—

 
—

 
(842
)
 Net (gain) loss on divestiture of businesses
 
(783
)
 
(862
)
 
1,770

 
(1,370
)
Amortization of property "step up" to fair value
 
609

 
600

 
2,392

 
2,440

Restructuring (credit) charges
 
(185
)
 
5,465

 
3,143

 
40,708

COVID-19 incremental costs
 
749

 
—

 
749

 
—

Total operating income
 
$
157,765

 
$
140,878

 
$
536,973

 
$
411,465









STERIS plc
 
 
 
 
Consolidated Condensed Statements of Cash Flows
 
 
 
 
(in thousands)
 
 
 
 
 
 
Twelve Months Ended March 31,
 
 
2020
 
2019
Operating activities:
 
(Unaudited)
 
(Unaudited)
Net income
 
$
407,805

 
$
305,076

Non-cash items
 
232,491

 
224,532

Changes in operating assets and liabilities
 
(49,737
)
 
9,897

Net cash provided by operating activities
 
590,559

 
539,505

Investing activities:
 
 
 
 
Purchases of property, plant, equipment, and intangibles, net
 
(214,516
)
 
(189,715
)
Proceeds from the sale of property, plant, equipment, and intangibles
 
4,156

 
5,567

Proceeds from the sale of businesses
 
439

 
2,478

Purchase of investments
 
—

 
(4,955
)
Acquisition of businesses, net of cash acquired
 
(109,814
)
 
(13,313
)
Other
 
—

 
(13,286
)
Net cash used in investing activities
 
(319,735
)
 
(213,224
)
Financing activities:
 
 
 
 
Payments on long-term obligations
 
—

 
(85,000
)
Payments under credit facilities, net
 
(26,500
)
 
(27,087
)
Deferred financing fees and debt issuance costs
 
(1,281
)
 
(488
)
Acquisition related deferred or contingent consideration
 
(626
)
 
(1,327
)
Repurchases of ordinary shares
 
(51,241
)
 
(81,494
)
Cash dividends paid to ordinary shareholders
 
(123,034
)
 
(112,503
)
Distributions to noncontrolling interest
 
(1,245
)
 
(255
)
Contributions from noncontrolling interest
 
6,050

 
—

Stock option and other equity transactions, net
 
34,731

 
13,362

Net cash used in financing activities
 
(163,146
)
 
(294,792
)
Effect of exchange rate changes on cash and cash equivalents
 
(8,730
)
 
(12,390
)
Increase in cash and cash equivalents
 
98,948

 
19,099

Cash and cash equivalents at beginning of period
 
220,633

 
201,534

Cash and cash equivalents at end of period
 
$
319,581

 
$
220,633

The following table presents a financial measure which is considered to be "non-GAAP financial measures" under Securities Exchange Commission rules. Free cash flow is defined by the Company as cash flows from operating activities less purchases of property, plant, equipment and intangibles (capital expenditures) plus proceeds from the sale of property, plant, equipment and intangibles. The Company uses free cash flow as a measure to gauge its ability to pay cash dividends, fund growth outside of core operations, fund future debt principal repayments, and repurchase shares. STERIS's calculation of free cash flows may vary from other companies.
 
 
Twelve Months Ended March 31,
 
 
2020
 
2019
 
 
(Unaudited)
 
(Unaudited)
Calculation of Free Cash Flow:
 
 
 
 
Cash flows from operating activities
 
$
590,559

 
$
539,505

Purchases of property, plant, equipment, and intangibles, net
 
(214,516
)
 
(189,715
)
Proceeds from the sale of property, plant, equipment, and intangibles
 
4,156

 
5,567

Free Cash Flow
 
$
380,199

 
$
355,357






STERIS plc
Non-GAAP Financial Measures
(in thousands, except per share data)
Non-GAAP financial measures are presented with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented.
Management and the Board of Directors believe that the presentation of these non-GAAP financial measures, when considered along with our GAAP financial measures and the reconciliation to the corresponding GAAP financial measures, provides the reader with a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. It is important for the reader to note that the non-GAAP financial measure used may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.
To measure the percentage organic revenue growth, the Company removes the impact of acquisitions and divestitures that affect the comparability and trends in revenue. To measure the percentage constant currency organic revenue growth, the impact of changes in currency exchange rates and acquisitions and divestitures that affect the comparability and trends in revenue are removed. The impact of changes in currency exchange rates is calculated by translating current year results at prior year average currency exchange rates.
 
 
Three months ended March 31, (unaudited)
 
 
As reported, GAAP
 
Impact of Acquisitions
 
Impact of Divestitures
 
Impact of Foreign Currency Movements
 
GAAP Growth
 
Organic Growth
 
Constant Currency Organic Growth
 
 
2020
 
2019
 
2020
 
2019
 
2020
 
2020
 
2020
 
2020
Segment revenues:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Healthcare Products
 
$
397,777

 
$
386,649

 
$
—

 
$
—

 
$
(1,257
)
 
2.9
%
 
2.9
%
 
3.2
%
Healthcare Specialty Services
 
148,795

 
135,493

 
—

 
(1,225
)
 
(440
)
 
9.8
%
 
10.8
%
 
11.1
%
Life Sciences
 
112,731

 
102,987

 
—

 
—

 
(569
)
 
9.5
%
 
9.5
%
 
10.0
%
Applied Sterilization Technologies
 
163,688

 
143,084

 
—

 
—

 
(1,499
)
 
14.4
%
 
14.4
%
 
15.4
%
Total
 
$
822,991

 
$
768,213

 
$
—

 
$
(1,225
)
 
$
(3,765
)
 
7.1
%
 
7.3
%
 
7.8
%
 
 
Twelve months ended March 31, (unaudited)
 
 
As reported, GAAP
 
Impact of Acquisitions
 
Impact of Divestitures
 
Impact of Foreign Currency Movements
 
GAAP Growth
 
Organic Growth
 
Constant Currency Organic Growth
 
 
2020
 
2019
 
2020
 
2019
 
2020
 
2020
 
2020
 
2020
Segment revenues:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Healthcare Products
 
$
1,423,198

 
$
1,338,428

 
$
—

 
$
—

 
$
(4,794
)
 
6.3
%
 
6.3
%
 
6.7
%
Healthcare Specialty Services
 
563,611

 
510,057

 
—

 
(4,485
)
 
(3,874
)
 
10.5
%
 
11.5
%
 
12.2
%
Life Sciences
 
416,939

 
378,558

 
—

 
—

 
(3,152
)
 
10.1
%
 
10.1
%
 
11.0
%
Applied Sterilization Technologies
 
627,147

 
555,127

 
—

 
—

 
(8,542
)
 
13.0
%
 
13.0
%
 
14.5
%
Total
 
$
3,030,895

 
$
2,782,170

 
$
—

 
$
(4,485
)
 
$
(20,362
)
 
8.9
%
 
9.1
%
 
9.8
%
 
 
Three months ended March 31, (unaudited)
 
 
Gross Profit
 
Income from Operations
 
Net Income attributable to shareholders
 
Diluted EPS
 
 
2020
 
2019
 
2020
 
2019
 
2020
 
2019
 
2020
 
2019
GAAP
 
$
364,060

 
$
334,716

 
$
157,765

 
$
140,878

 
$
123,316

 
$
108,745

 
$
1.44

 
$
1.27

Adjustments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amortization of acquired intangible assets
 
331

 
149

 
18,268

 
17,971

 
 
 
 
 
 
 
 
Acquisition and integration related charges
 
283

 
698

 
2,640

 
2,704

 
 
 
 
 
 
 
 
Redomiciliation and tax restructuring costs
 
—

 
—

 
425

 
3,150

 
 
 
 
 
 
 
 
 Net (gain) on divestiture of businesses
 
—

 
—

 
(783
)
 
(862
)
 
 
 
 
 
 
 
 
Amortization of property "step up" to fair value
 
608

 
648

 
609

 
600

 
 
 
 
 
 
 
 
COVID-19 incremental costs
 
475

 
—

 
749

 
—

 
 
 
 
 
 
 
 
Restructuring (credit) charges 
 
(191
)
 
625

 
(185
)
 
5,465

 
 
 
 
 
 
 
 
Net impact of adjustments after tax*
 
 
 
 
 
 
 
 
 
17,178

 
22,308

 
 
 
 
Net EPS impact
 
 
 
 
 
 
 
 
 
 
 
 
 
0.20

 
0.26

Adjusted
 
$
365,566

 
$
336,836

 
$
179,488

 
$
169,906

 
$
140,494

 
$
131,053

 
$
1.64

 
$
1.53

* The tax expense includes both the current and deferred income tax impact of the adjustments.






STERIS plc
Non-GAAP Financial Measures (Continued)
(in thousands, except per share data)
 
 
Twelve months ended March 31, (unaudited)
 
 
Gross Profit
 
Income from Operations
 
Net Income attributable to shareholders
 
Diluted EPS
 
 
2020
 
2019
 
2020
 
2019
 
2020
 
2019
 
2020
 
2019
GAAP
 
$
1,319,923

 
$
1,175,427

 
$
536,973

 
$
411,465

 
$
407,605

 
$
304,051

 
$
4.76

 
$
3.56

Adjustments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amortization of acquired intangible assets
 
1,566

 
721

 
71,675

 
86,878

 
 
 
 
 
 
 
 
Acquisition and integration related charges
 
1,583

 
2,145

 
8,225

 
8,901

 
 
 
 
 
 
 
 
Redomiciliation and tax restructuring costs
 
—

 
—

 
3,699

 
8,783

 
 
 
 
 
 
 
 
(Gain) on fair value adjustment of acquisition related contingent consideration
 
—

 
—

 
—

 
(842
)
 
 
 
 
 
 
 
 
 Net loss (gain) on divestiture of businesses
 
—

 
—

 
1,770

 
(1,370
)
 
 
 
 
 
 
 
 
Amortization of property "step up" to fair value
 
2,499

 
2,604

 
2,392

 
2,440

 
 
 
 
 
 
 
 
COVID-19 incremental costs
 
475

 
—

 
749

 
—

 
 
 
 
 
 
 
 
Restructuring charges 
 
2,470

 
9,721

 
3,143

 
40,708

 
 
 
 
 
 
 
 
Net impact of adjustments after tax*
 
 
 
 
 
 
 
 
 
75,019

 
113,497

 
 
 
 
Net EPS impact
 
 
 
 
 
 
 
 
 
 
 
 
 
0.88

 
1.33

Adjusted
 
$
1,328,516

 
$
1,190,618

 
$
628,626

 
$
556,963

 
$
482,624

 
$
417,548

 
$
5.64

 
$
4.89

* The tax expense includes both the current and deferred income tax impact of the adjustments.







STERIS plc
 
 
 
 
 
Unaudited Supplemental Financial Data
 
 
 
 
Fourth Quarter Fiscal 2020
 
 
 
For the Periods Ending March 31, 2020 and 2019
 
 
 
 
 
 
FY 2020
FY 2019
FY 2020
FY 2019
Total Company Revenues
Q4
Q4
YTD
YTD
Consumables
$
177,020

$
154,902

$
672,329

$
605,631

Service
429,399

393,276

1,628,107

1,486,145

Total Recurring
$
606,419

$
548,178

$
2,300,436

$
2,091,776

Capital Equipment
$
216,572

$
220,035

$
730,459

$
690,394

Total Revenues
$
822,991

$
768,213

$
3,030,895

$
2,782,170

Ireland Revenues
$
17,416

$
15,911

$
63,821

$
56,784

Ireland Revenues as a % of Total
2
%
2
%
2
%
2
%
United States Revenues
$
599,967

$
553,713

$
2,211,722

$
1,976,814

United States Revenues as a % of Total
73
%
72
%
73
%
71
%
International Revenues
$
205,608

$
198,589

$
755,352

$
748,572

International Revenues as a % of Total
25
%
26
%
25
%
27
%
 
 
 
 
 
 
Segment Data
 
FY 2020
FY 2019
FY 2020
FY 2019
Healthcare Products
 
Q4
Q4
YTD
YTD
Revenues
 
 
 
 
Consumables
 
$
115,827

$
105,424

$
454,518

$
414,969

Service
 
99,763

96,500

376,244

354,648

Total Recurring
$
215,590

$
201,924

$
830,762

$
769,617

Capital Equipment
 
182,187

184,725

592,436

568,811

Total Healthcare Products Revenues
$
397,777

$
386,649

$
1,423,198

$
1,338,428

Segment Operating Income
$
105,909

$
106,673

$
356,419

$
323,684

 
 
 
 
 
 
Healthcare Specialty Services
 
 
 
 
Healthcare Services Revenues
$
148,795

$
135,493

$
563,611

$
510,057

Segment Operating Income
$
15,950

$
19,800

$
64,217

$
64,222

 
 
 
 
 
 
Life Sciences
 
 
 
 
 
Revenues
 
 
 
 
Consumables
 
$
52,965

$
41,936

$
185,904

$
161,780

Service
 
32,012

30,626

118,288

114,064

Total Recurring
$
84,977

$
72,562

$
304,192

$
275,844

Capital Equipment
 
27,754

30,425

112,747

102,714

Total Life Sciences Revenues
 
$
112,731

$
102,987

$
416,939

$
378,558

Segment Operating Income
$
41,003

$
35,869

$
144,088

$
132,129

 
 
 
 
 
 
Applied Sterilization Technologies
 
 
 
 
Applied Sterilization Technologies Revenues
$
163,688

$
143,084

$
627,147

$
555,127

Segment Operating Income
$
72,028

$
57,411

$
270,917

$
221,828

 
 
 
 
 
 
Corporate
 
 
 
 
 
Operating loss
 
$
(55,402
)
$
(49,847
)
$
(207,015
)
$
(184,900
)
 
 
 
 
 
 
Other Data
 
FY 2020
FY 2019
FY 2020
FY 2019
 
 
Q4
Q4
YTD
YTD
Healthcare Products Backlog
 
$
170,101

$
154,480

 
 
Life Sciences Backlog
 
72,390

60,702

 
 
Total Backlog
 
$
242,491

$
215,182

 
 
 
 
 
 
 
 
GAAP Income Tax Rate
16.8
%
18.4
%
18.2
%
17.4
%
Adjusted Income Tax Rate
17.3
%
19.2
%
18.2
%
18.7
%
This supplemental data is consistent with publicly disclosed information provided in quarterly conference calls, earnings releases and SEC filings, and is subject to all definitions, precautions and limitations contained in those disclosures. Please see the Company's most recent 10-K for definitions (and reconciliation where appropriate) of adjusted measures, backlog, free cash flow and net debt.




STERIS plc
 
 
 
 
Recast of Fiscal 2020 Segment Data By Quarter
 
 
 
 
 
 
 
 
Effective April 1, 2020, and consistent with the way management will operate and view the business, the current Healthcare Products and Healthcare Specialty Services segments will be combined and reported as one segment, simply called Healthcare. Financial information for each of the segments is presented in the following table. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. Segment income is calculated as the segment’s gross profit less direct costs and indirect costs if the resources are dedicated to a single segment. Corporate costs include corporate and administrative functions, public company costs, legacy post-retirement benefits, and certain services and facilities related to distribution and research and development that are shared by multiple segments.

(dollars in thousands)
Fiscal Year Ending March 31, 2020 (unaudited)
 
Q1
 
Q2
 
Q3
 
Q4
 
Full Year
Revenues:
 
 
 
 
 
 
 
 
 
Healthcare
$
445,732

 
$
485,283

 
$
509,222

 
$
546,572

 
$
1,986,809

Life Sciences
96,785

 
98,650

 
108,773

 
112,731

 
416,939

Applied Sterilization Technologies
154,286

 
152,907

 
156,266

 
163,688

 
627,147

Total revenues
$
696,803

 
$
736,840

 
$
774,261

 
$
822,991

 
$
3,030,895

Operating income (loss):
 
 
 
 
 
 
 
 
 
Healthcare
$
90,515

 
$
103,035

 
$
105,227

 
$
121,859

 
$
420,636

Life Sciences
33,039

 
32,315

 
37,731

 
41,003

 
144,088

Applied Sterilization Technologies
68,035

 
65,386

 
65,468

 
72,028

 
270,917

Corporate
(55,397
)
 
(50,956
)
 
(45,260
)
 
(55,402
)
 
(207,015
)
Total operating income before adjustments
$
136,192

 
$
149,780

 
$
163,166

 
$
179,488

 
$
628,626



 EX-101.SCH 3 ste-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0004000 - Document - Cover Page Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 ste-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 ste-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 ste-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Central Index Key Entity Central Index Key Title of 12(b) Security Title of 12(b) Security Document Type Document Type Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material Written Communications Written Communications Entity Address, Country Entity Address, Country Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Local Phone Number Local Phone Number Document Period End Date Document Period End Date Country Region Country Region City Area Code City Area Code Entity Registrant Name Entity Registrant Name Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 7 ste-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} ZIP 9 0001757898-20-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001757898-20-000008-xbrl.zip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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page Cover Page
May 13, 2020
Cover [Abstract]  
Entity Incorporation, State or Country Code L2
Entity Central Index Key 0001757898
Title of 12(b) Security Ordinary Shares
Document Type 8-K
Pre-commencement Issuer Tender Offer false
Pre-commencement Tender Offer false
Soliciting Material false
Written Communications false
Entity Address, Country IE
Entity File Number 001-38848
Entity Tax Identification Number 98-1455064
Local Phone Number 232 2000
Document Period End Date May 13, 2020
Country Region 353
City Area Code 1
Entity Registrant Name STERIS plc
Entity Address, Address Line One 70 Sir John Rogerson's Quay,
Entity Address, City or Town Dublin 2,
Trading Symbol STE
Security Exchange Name NYSE
Amendment Flag false
Entity Address, Postal Zip Code D02 R296
Entity Emerging Growth Company false

XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 96 1 false 0 0 false 0 false false R1.htm 0004000 - Document - Cover Page Cover Page Sheet http://www.steris.com/role/CoverPageCoverPage Cover Page Cover Page Cover 1 false false All Reports Book All Reports ste03312020form8-k.htm ste-20200331.xsd ste-20200331_cal.xml ste-20200331_def.xml ste-20200331_lab.xml ste-20200331_pre.xml ste03312020ex991.htm http://xbrl.sec.gov/dei/2019-01-31 true true XML 12 ste03312020form8-k_htm.xml IDEA: XBRL DOCUMENT 0001757898 2020-05-13 2020-05-13 false 0001757898 false L2 false false 8-K 2020-05-13 STERIS plc L2 001-38848 98-1455064 70 Sir John Rogerson's Quay, Dublin 2, IE D02 R296 353 1 232 2000 false false false false Ordinary Shares STE NYSE EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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etaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ste03312020form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "ste-20200331_cal.xml" ] }, "definitionLink": { "local": [ "ste-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "ste03312020form8-k.htm" ] }, "labelLink": { "local": [ "ste-20200331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ste-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ste-20200331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 6 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ste", "nsuri": "http://www.steris.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ste03312020form8-k.htm", "contextRef": "D2020Q4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12bTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0004000 - Document - Cover Page Cover Page", "role": "http://www.steris.com/role/CoverPageCoverPage", "shortName": "Cover Page Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "ste03312020form8-k.htm", "contextRef": "D2020Q4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12bTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region", "terseLabel": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.steris.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }